In Vitro and In Vivo Characterization of 40 kDa PEGylated Adrenomedullin in a DSS-Induced Colitis Model.

Kazuo Kitamura, Emiko Akashi, Sayaka Nagata, Toshihiro Kita, Motoo Yamasaki

Abstract read

In one paragraph

Article in International journal of molecular sciences, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it

0cells of the map it votes in

0citing papers in PubMed

–field-weighted citation impact

1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Kazuo KitamuraDepartment of Project Research, Frontier Science Research Center, University of Miyazaki, Miyazaki 889-1692, Japan.ORCID 0000-0002-5124-9549

Emiko AkashiDepartment of Project Research, Frontier Science Research Center, University of Miyazaki, Miyazaki 889-1692, Japan.

Sayaka NagataDepartment of Project Research, Frontier Science Research Center, University of Miyazaki, Miyazaki 889-1692, Japan.

Toshihiro KitaDepartment of Project Research, Frontier Science Research Center, University of Miyazaki, Miyazaki 889-1692, Japan.ORCID 0000-0003-1903-9012

Motoo YamasakiDepartment of Project Research, Frontier Science Research Center, University of Miyazaki, Miyazaki 889-1692, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Adrenomedullin (AM), a biologically active peptide, induces complete remission with mucosal healing in patients with refractory ulcerative colitis. We have developed 40 kDa PEGylated AM (PEG-AM), a long-acting AM derivative, as a potential therapeutic agent for inflammatory bowel disease (IBD). Both PEG-AM and native AM stimulated cyclic adenosine monophosphate (cAMP) production in HEK-293 cells stably expressing the AM1 receptor (CLR/RAMP2 complex), in a dose-dependent manner. The pEC

Indexed as

AdrenomedullinColitisPolyethylene GlycolsAnimalsCyclic AMPDextran SulfateDisease Models, AnimalHEK293 CellsHumansMaleMiceMice, Inbred C57BLAdrenomedullinCyclic AMPDextran SulfatePolyethylene Glycols40 kDa PEGylated AM (PEG-AM)adrenomedullin (AM)cAMPcolitisdextran sodium sulfate (DSS)inflammatory bowel diseasereceptor

Identifiers

PMID41096644

DOI10.3390/ijms26199373

PMCPMC12524408

What OpenQuestion holds

Textmetadata

LicenceCC BY

Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.